BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Last update: 4 days ago, 4:31PM

59.67

0.53 (0.90%)

  • 1D 0.90%
  • 5D 6.00%
  • 1M 6.44%
  • 6M 21.83%
  • YTD 5.07%
  • 1Y 19.65%
  • 5Y -7.93%
Previous Close 59.14
Open 59.11
Volume 12,325,719
Avg. Volume (3M) 10,969,145
Market Cap 121,021,497,344
Price / Earnings (Forward) 8.50
Price / Sales 2.55
Price / Book 7.06
52 Weeks Range
39.35 (-34%) — 61.08 (2%)
Earnings Date 6 Feb 2025
TTM Dividend Yield 4.02%
Profit Margin -15.30%
Operating Margin (TTM) 18.48%
Diluted EPS (TTM) -3.58
Quarterly Revenue Growth (YOY) 8.40%
Quarterly Earnings Growth (YOY) -37.20%
Total Debt/Equity (MRQ) 299.05%
Current Ratio (MRQ) 1.24
Operating Cash Flow (TTM) 15.00 B
Levered Free Cash Flow (TTM) 17.52 B
Return on Assets (TTM) 6.07%
Return on Equity (TTM) -31.33%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bearish Mixed
Drug Manufacturers - General (Global) Bearish Mixed
Stock Bristol-Myers Squibb Company Bullish Bullish

AIStockmoo Score

0.5
Analyst Consensus 1.5
Insider Activity NA
Price Volatility -3.5
Technical Moving Averages 0.0
Technical Oscillators 4.0
Average 0.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
BMY 121 B 4.02% - 7.06
JNJ 362 B 3.27% 25.97 4.99
ABBV 310 B 3.54% 61.03 49.89
PFE 152 B 6.28% 35.67 1.65
GSK 70 B 4.54% 23.00 3.73
LLY 706 B 0.66% 84.63 50.52

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.12%
% Held by Institutions 78.52%
52 Weeks Range
39.35 (-34%) — 61.08 (2%)
Price Target Range
39.00 (-34%) — 73.00 (22%)
High 73.00 (Leerink Partners, 22.34%) Buy
Median 65.00 (8.93%)
Low 39.00 (Morgan Stanley, -34.64%) Sell
Average 62.29 (4.39%)
Total 3 Buy, 3 Hold, 1 Sell
Avg. Price @ Call 58.35
Firm Date Target Price Call Price @ Call
Citigroup 28 Jan 2025 65.00 (8.93%) Hold 60.60
12 Nov 2024 60.00 (0.55%) Hold 59.02
Truist Securities 08 Jan 2025 65.00 (8.93%) Buy 56.81
Jefferies 16 Dec 2024 70.00 (17.31%) Buy 55.87
B of A Securities 10 Dec 2024 63.00 (5.58%) Hold 58.12
BMO Capital 12 Nov 2024 61.00 (2.23%) Hold 59.02
01 Nov 2024 57.00 (-4.47%) Hold 54.32
Leerink Partners 12 Nov 2024 73.00 (22.34%) Buy 59.02
Morgan Stanley 12 Nov 2024 39.00 (-34.64%) Sell 59.02

No data within this time range.

  • 3M
Date Type Details
25 Jan 2025 Announcement Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
15 Jan 2025 CNBC Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
13 Jan 2025 Announcement ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
03 Jan 2025 Announcement Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
27 Dec 2024 Announcement U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2
23 Dec 2024 Announcement Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
23 Dec 2024 Announcement Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
19 Dec 2024 Announcement Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
19 Dec 2024 Announcement BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
18 Dec 2024 Announcement insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS
11 Dec 2024 Announcement Bristol Myers Squibb Announces Dividend Increase
09 Dec 2024 Announcement Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline
03 Dec 2024 Announcement AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
26 Nov 2024 Announcement Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference
19 Nov 2024 Announcement Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
15 Nov 2024 Announcement Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
15 Nov 2024 Announcement Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
11 Nov 2024 Announcement Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
05 Nov 2024 Announcement Bristol Myers Squibb to Participate in Upcoming Investor Conferences
31 Oct 2024 Announcement Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
31 Oct 2024 Announcement Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
31 Oct 2024 CNBC Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
28 Oct 2024 Announcement Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
Show more
TTM Dividend Yield 4.02%
5Y Average Dividend Yield 3.55%
Payout Ratio 59.84%
Expected Next Dividend Payment May 2025
Ex Date Announcement Date Payment Date Details
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 Cash
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 Cash
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Cash
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Cash
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Cash
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Cash
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Cash
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Cash
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Cash
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Cash
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Cash
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Cash
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Cash
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Cash
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Cash
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Cash
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Cash
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Cash
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Cash
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Cash
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Cash
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Cash
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Cash
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Cash
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Cash
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Cash
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Cash
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Cash
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Cash
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Cash
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Cash
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Cash
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Cash
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Cash
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Cash
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Cash
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Cash
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Cash
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Cash
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Cash
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Cash
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Cash
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Cash
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Cash
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Cash
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Cash
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 0.620 1 1.04
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria